Solventum Corp Files 8-K

Ticker: SOLV · Form: 8-K · Filed: 2025-08-13T00:00:00.000Z

Sentiment: neutral

Topics: corporate-action, spin-off, filing

TL;DR

Solventum Corp is officially a thing, formerly 3M Health Care.

AI Summary

Solventum Corporation, formerly 3M Health Care Co, filed an 8-K on August 13, 2025, reporting on its status as a newly independent entity. The filing indicates its incorporation in Delaware with EIN 922008841 and its principal executive offices located at 3M Center, St. Paul, MN.

Why It Matters

This filing marks a significant corporate event for Solventum, indicating its transition to a standalone public company, which could impact its strategic direction and investor relations.

Risk Assessment

Risk Level: low — The filing is a routine corporate disclosure and does not contain information that inherently increases risk.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Solventum Corporation?

This 8-K filing serves as a current report for Solventum Corporation, indicating its status and providing essential corporate information as of August 13, 2025.

What was Solventum Corporation's former name?

Solventum Corporation was formerly known as 3M Health Care Co.

In which state is Solventum Corporation incorporated?

Solventum Corporation is incorporated in Delaware.

What is the SEC file number for Solventum Corporation?

The SEC file number for Solventum Corporation is 001-41968.

Where are Solventum Corporation's principal executive offices located?

Solventum Corporation's principal executive offices are located at 3M Center, Building 275-6W, East Maplewood, MN 55144.

From the Filing

0001140361-25-030803.txt : 20250813 0001140361-25-030803.hdr.sgml : 20250813 20250813161223 ACCESSION NUMBER: 0001140361-25-030803 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250813 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250813 DATE AS OF CHANGE: 20250813 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Solventum Corp CENTRAL INDEX KEY: 0001964738 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 922008841 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41968 FILM NUMBER: 251211718 BUSINESS ADDRESS: STREET 1: C/O 3M COMPANY STREET 2: 3M CENTER, BUILDING 275-6W-02 CITY: ST. PAUL STATE: MN ZIP: 55144-1000 BUSINESS PHONE: 651-733-1110 MAIL ADDRESS: STREET 1: C/O 3M COMPANY STREET 2: 3M CENTER, BUILDING 275-6W-02 CITY: ST. PAUL STATE: MN ZIP: 55144-1000 FORMER COMPANY: FORMER CONFORMED NAME: 3M Health Care Co DATE OF NAME CHANGE: 20230203 8-K 1 ef20053560_8k.htm 8-K false 0001964738 0001964738 2025-08-13 2025-08-13 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 13, 2025 SOLVENTUM CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-41968 92-2008841 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 3M Center, Building 275-6W 2510 Conway Avenue East Maplewood , MN 55144 (Address of principal executive offices) (Zip Code) ( 651 ) 733-1110 (Registrant’s telephone number, including area code) Not Applicable (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:     ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of exchange on which registered Common Stock, $0.01 par value SOLV New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 7.01 Regulation FD Pro Forma Financial Information Included in Item 9.01 of this Current Report on Form 8-K, are unaudited pro forma condensed consolidated financial statements (the “pro forma financial statements”) of Solventum Corporation, a Delaware corporation (“Solventum” or the “Company”) relating to Solventum’s previously announced Transaction (as defined below) with Thermo Fisher Scientific Inc., a Delaware corporation (“Buyer”). The pro forma financial statements have been prepared in accordance with Article 11 of Regulation S-X and do not purport to reflect what the Company’s actual results of operations or fin

View on Read The Filing